Estrogen Dominance: Naturopathic Assessment, Root Causes, and Evidence-Based Protocols

A clinical naturopathic guide to estrogen dominance — covering the oestrogen:progesterone ratio imbalance, Phase 1/2 liver detoxification pathways, the oestrobolome, xenoestrogen exposure, and evidence-ranked dietary, herbal, and lifestyle protocols.

Educational disclaimer: This article is written for health professionals and informed consumers seeking to understand the naturopathic and functional medicine approach to oestrogen balance. It does not constitute medical advice. Hormone-related symptoms should be assessed and managed by a qualified practitioner. Testing, supplementation, and herbal protocols should be individualised.

What Estrogen Dominance Actually Is — And What It Is Not

The term estrogen dominance is frequently misunderstood, even in clinical settings. A common assumption is that it simply means high circulating oestrogen levels — but this is a reductive and clinically incomplete definition. Estrogen dominance is more accurately described as a state in which oestrogen activity is disproportionately elevated relative to progesterone, regardless of whether absolute oestrogen levels are high, normal, or even low.

This distinction matters enormously in clinical practice. A perimenopausal woman with falling oestradiol levels may still present with classic estrogen dominance symptoms if her progesterone has dropped even more precipitously. Conversely, a woman in her late twenties with textbook serum oestradiol may be functionally oestrogen dominant because her luteal-phase progesterone is insufficient, her liver is processing oestrogen through genotoxic pathways, or her gut microbiome is actively reabsorbing deconjugated oestrogens back into circulation.

The clinical picture is therefore defined not by a single hormone level but by a ratio imbalance operating across multiple physiological systems simultaneously — hepatic detoxification, gut microbiome ecology, adipose tissue aromatase activity, cellular receptor sensitivity, and the adrenal-progesterone axis. A thorough naturopathic assessment addresses each of these layers rather than targeting circulating oestradiol in isolation.

Root Causes: A Systems-Level Framework

Phase 1 Liver Detoxification: CYP Enzymes and Catechol Oestrogen Accumulation

The liver is the primary site of oestrogen biotransformation. In Phase 1 detoxification, the cytochrome P450 enzyme family hydroxylates oestrogens into three main metabolite streams:

2-hydroxyoestrone (2-OH-E1): The preferred "protective" pathway. 2-OH metabolites have weak oestrogenic activity, do not significantly stimulate oestrogen receptors, and are efficiently cleared.
4-hydroxyoestrone (4-OH-E1): A catechol oestrogen generated primarily by CYP1B1. 4-OH metabolites are potentially genotoxic — they can form quinone intermediates that bind to DNA and create depurinating adducts. Elevated 4-OH-E1 on a DUTCH panel is a meaningful clinical signal.
16-alpha-hydroxyoestrone (16-OH-E1): A strongly oestrogenic metabolite associated with increased tissue proliferation and linked epidemiologically to hormone-sensitive conditions.

CYP1B1 enzyme activity — the primary driver of the 4-OH pathway — is upregulated by factors including chronic inflammation, pesticide exposure, and certain dietary patterns. Genetic polymorphisms in CYP1B1 can further shift the balance toward catechol oestrogen production. Rosemary (via its constituent carnosol) has been investigated as a CYP1A1 inducer, potentially supporting the 2-OH pathway, though evidence remains largely preclinical.

Phase 2 Detoxification: Methylation Defects and Oestrogen Glucuronidation

Once hydroxylated in Phase 1, oestrogen metabolites must be conjugated in Phase 2 to become water-soluble for excretion. Two Phase 2 pathways are most clinically relevant:

Methylation via COMT: The catechol-O-methyltransferase (COMT) enzyme methylates catechol oestrogens (particularly 4-OH-E1) using the methyl donor S-adenosylmethionine (SAMe). Impaired COMT activity — whether from genetic variants (COMT Val158Met polymorphism), magnesium deficiency, or depleted SAMe — allows catechol oestrogens to accumulate and oxidise into reactive quinones rather than being safely cleared.

MTHFR and methylation capacity: The MTHFR enzyme is upstream of COMT function. MTHFR polymorphisms (C677T, A1298C) reduce conversion of folate to 5-methyltetrahydrofolate, limiting the methyl groups available for SAMe synthesis. This creates a systemic methylation bottleneck that impairs COMT-mediated oestrogen clearance. Patients with confirmed MTHFR variants who also have symptoms of estrogen dominance require a dual approach addressing both hormonal and methylation pathways.

Glucuronidation via UGT enzymes: Oestrogens are also conjugated to glucuronic acid (UGT enzymes) and excreted in bile. This conjugation step is vulnerable to gut-level interference, as discussed below.

Gut Dysbiosis and the Oestrobolome

The oestrobolome refers to the aggregate of gut microbial genes encoding enzymes capable of metabolising oestrogens — most notably, beta-glucuronidase. Certain bacterial species, including some strains of Clostridium, Bacteroides, and Escherichia, produce beta-glucuronidase at elevated levels when dysbiosis is present.

Beta-glucuronidase deconjugates oestrogen-glucuronide complexes that have been processed by the liver and released into the gut via bile. Once deconjugated, free oestrogens are reabsorbed through the enterohepatic circulation rather than excreted in stool — effectively recirculating oestrogen that the liver had already prepared for elimination. This oestrobolome-driven recirculation can meaningfully raise systemic oestrogen exposure even when hepatic Phase 1 and 2 function is adequate.

SIBO and gut dysbiosis are therefore directly relevant to oestrogen balance: small intestinal bacterial overgrowth creates a dysbiotic microbiome environment that drives beta-glucuronidase activity, impairs oestrogen clearance, and sustains enterohepatic recirculation. Naturopathic treatment of underlying dysbiosis is a core component of estrogen dominance management, not an optional adjunct.

Research published in mSystems (2019) and subsequent work by Plottel and Blaser have formalised the oestrobolome concept, with increasing evidence that microbiome diversity and Lactobacillus-dominant communities are associated with lower beta-glucuronidase activity and more efficient oestrogen clearance.

Xenoestrogens: Environmental Endocrine Disruption

Exogenous chemicals capable of binding oestrogen receptors — xenoestrogens — represent a significant environmental contributor to estrogen dominance that is often underweighted in conventional assessment. Key xenoestrogen classes include:

Bisphenol A (BPA) and BPA substitutes (BPS, BPF): Found in food-contact plastics, thermal paper receipts, and tin can linings. BPA binds oestrogen receptor alpha and has been associated with reproductive disruption in multiple animal models and human observational studies.
Phthalates: Plasticisers found in food packaging, cosmetics, personal care products, and PVC materials. Phthalates act as anti-androgens as well as weak oestrogens, contributing to the hormonal milieu.
Parabens: Preservatives in cosmetics and personal care products with demonstrable oestrogenic activity in in vitro and in vivo studies.
Herbicides and pesticides: Organochlorine pesticides (including historic DDT and its persistent metabolite DDE) and many contemporary herbicide compounds have measurable oestrogenic or anti-androgenic activity.

Xenoestrogen burden is cumulative and additive. A naturopathic assessment of estrogen dominance that does not evaluate exposure history — personal care products, dietary packaging practices, occupational exposure — is incomplete. Practical reduction strategies (glass and stainless steel food storage, fragrance-free personal care, organic food prioritisation) are primary prevention measures with low risk and meaningful potential benefit.

Adipose Tissue Aromatase and Body Composition

The aromatase enzyme (CYP19A1) converts androgens — primarily androstenedione and testosterone — into oestrone (E1). Adipose tissue is the dominant site of aromatase activity outside the gonads, and aromatase expression in adipose tissue increases proportionally with adiposity and with age.

In practice, this means that increased body fat percentage directly amplifies oestrogen production from a non-ovarian source, creating a self-reinforcing cycle: elevated oestrogen promotes fat accumulation (particularly in oestrogen-receptor-rich depots such as hips, thighs, and breasts), and increased adiposity drives further aromatase-mediated oestrogen production. Alcohol consumption significantly upregulates aromatase activity — a mechanistically important reason why alcohol reduction is a high-priority dietary intervention for estrogen dominance.

Progesterone Deficiency: Anovulation and Perimenopause

Absolute or relative progesterone deficiency is a common and clinically straightforward driver of the oestrogen:progesterone imbalance. Sources include:

Anovulatory cycles: Without ovulation, no corpus luteum forms and luteal-phase progesterone production does not occur. Anovulation is common in polycystic ovary syndrome (PCOS), hypothalamic amenorrhoea, thyroid dysfunction, and under high-stress or under-fuelled states.
Perimenopause: Progesterone production declines earlier and more steeply than oestradiol in perimenopause, creating a window of relative oestrogen dominance even as total oestrogen is falling.
Luteal phase insufficiency: Some women ovulate but produce insufficient progesterone during the luteal phase — a pattern detectable on properly timed luteal-phase serum progesterone or DUTCH testing.

Clinical Presentation and Symptom Patterns

The symptom constellation of estrogen dominance spans reproductive, metabolic, and neurological domains. Common presentations include:

Menstrual and reproductive: Heavy or prolonged periods, painful menstruation (dysmenorrhoea), mid-cycle spotting, breast tenderness and swelling (particularly premenstrually), worsening premenstrual syndrome (PMS), uterine fibroids, and elevated risk of endometriosis.

Metabolic: Difficulty losing weight despite appropriate dietary intake, fat redistribution to hips and thighs, fluid retention, bloating, and thyroid hormone binding protein elevation (oestrogen increases thyroxine-binding globulin, reducing free T4 and T3 availability).

Neurological and psychological: Irritability, anxiety, low mood (particularly premenstrually), brain fog, poor sleep, and headaches that track with the menstrual cycle.

Longer-term risk signals: Clinically significant and persistent estrogen dominance is associated with increased risk of oestrogen-sensitive conditions including endometriosis, uterine fibroids, and — with certain genotoxic oestrogen metabolites — hormone-sensitive cancers. These associations support the clinical importance of thorough assessment and targeted intervention.

Naturopathic Testing: Mapping the Biochemistry

DUTCH Test (Dried Urine Test for Comprehensive Hormones)

The DUTCH test is the most clinically informative single panel for naturopathic assessment of estrogen dominance. Its key advantages over serum testing:

Oestrogen metabolite mapping: Direct measurement of 2-OH-E1, 4-OH-E1, and 16-OH-E1 fractions reveals not just how much oestrogen is present, but how it is being metabolised. An elevated 4-OH:2-OH ratio indicates a shift toward the genotoxic pathway and is an actionable clinical finding.
Methylation pathway assessment: The 2-methoxyoestrone (2-MeO-E1) to 2-OH-E1 ratio reflects COMT enzyme activity. A low ratio indicates impaired methylation of catechol oestrogens — directly relevant to COMT and MTHFR status.
Progesterone metabolites: Measurement of alpha-pregnanediol and beta-pregnanediol provides insight into progesterone production and metabolism beyond a single serum value.
Cortisol pattern: Critical for assessing adrenal function and the cortisol-progesterone interplay described below.

DUTCH testing should ideally be collected in the mid-luteal phase (approximately day 19–22 of a 28-day cycle) to capture peak progesterone and evaluate the oestrogen:progesterone relationship at its most clinically informative point. For post-menopausal women or those on hormonal therapy, collection timing follows different protocols.

Serum Hormone Panel

A targeted serum panel provides complementary data, particularly when DUTCH is not accessible:

Oestradiol (E2): Best collected on days 2–4 (follicular baseline) and again in the mid-luteal phase. Interpretation requires cycle timing to be meaningful.
Progesterone: Luteal-phase collection only (days 19–22). A result below 16–18 nmol/L in the mid-luteal phase suggests luteal phase insufficiency in a symptomatic patient.
Sex hormone binding globulin (SHBG): SHBG modulates free oestrogen and androgen availability. Low SHBG (driven by insulin resistance, high androgens, hypothyroidism) increases free oestrogen availability independent of total oestrogen levels. High SHBG (driven by oestrogen excess, thyroid hormone) can mask true androgen production.
FSH: Elevated FSH (>10 IU/L in the early follicular phase) suggests reduced ovarian reserve and emerging perimenopause.
Thyroid panel (TSH, free T3, free T4, TPO antibodies): Thyroid dysfunction frequently accompanies and compounds estrogen dominance, and should not be omitted from the initial assessment.
Fasting insulin and glucose: Given the adiposity-aromatase relationship and the insulin-SHBG connection, metabolic markers are an essential component of a complete hormone workup.

Dietary Interventions: Evidence-Ranked

DIM (Diindolylmethane) from Cruciferous Vegetables

Diindolylmethane is produced from indole-3-carbinol (I3C) during the digestion of cruciferous vegetables (broccoli, Brussels sprouts, cauliflower, kale, cabbage). DIM has been studied as a modulator of oestrogen metabolism, specifically for its ability to promote the 2-OH pathway at the expense of the 16-OH and 4-OH pathways — effectively shifting Phase 1 hydroxylation toward the less proliferative metabolite stream.

A 2000 randomised trial by Bradlow et al. demonstrated a significant increase in the 2-OH:16-OH ratio following I3C supplementation in healthy women. Subsequent research has examined DIM supplementation directly, with consistent findings of favourable oestrogen metabolite ratio shifts in pre-menopausal women. Supplemental DIM doses in research typically range from 100–300 mg daily; dietary intake from 2–3 cups of cruciferous vegetables daily provides meaningful I3C but lower DIM concentrations.

Flaxseed and Lignans

Flaxseed is the richest dietary source of plant lignans — primarily secoisolariciresinol diglucoside (SDG) — which are converted by gut bacteria to the mammalian lignans enterolactone and enterodiol. These compounds exert weak oestrogenic and anti-oestrogenic effects depending on the hormonal context, and importantly, inhibit beta-glucuronidase activity in the gut, directly reducing oestrogen reabsorption from the enterohepatic circulation.

A 2007 study published in Cancer Epidemiology, Biomarkers & Prevention confirmed that urinary enterolactone levels (a proxy for lignan intake) were inversely associated with oestrone and oestradiol concentrations in post-menopausal women. In clinical practice, 1–2 tablespoons of freshly ground flaxseed daily (not flaxseed oil, which lacks the lignan fraction) is a practical and well-tolerated starting dose.

Calcium-D-Glucarate

Calcium-D-glucarate is the calcium salt of D-glucaric acid, a natural compound found in small amounts in fruits and vegetables. Its primary mechanism of action in estrogen dominance is direct inhibition of beta-glucuronidase — the gut enzyme responsible for deconjugating oestrogen-glucuronide complexes and enabling their reabsorption. By inhibiting beta-glucuronidase, calcium-D-glucarate supports the excretion of conjugated oestrogens rather than their recirculation.

Animal and in vitro research from the late 1990s (Walaszek et al.) established this mechanism. Clinical evidence in humans is more limited but the mechanistic rationale is compelling and safety is well-established. Typical supplemental doses studied range from 1.5–3 g daily. It pairs logically with flaxseed lignans for comprehensive beta-glucuronidase inhibition and oestrobolome support.

Fibre: Oestrogen Excretion via Stool

Adequate dietary fibre (25–35 g daily) supports oestrogen clearance through two mechanisms: it physically binds conjugated oestrogens in the gut, facilitating their excretion in stool; and it feeds Lactobacillus and Bifidobacterium species that are associated with lower beta-glucuronidase activity and a more favourable oestrobolome composition. In practice, this means prioritising whole food fibre sources — legumes, vegetables, whole grains, fruits — over isolated fibre supplements, which lack the prebiotic diversity of whole foods. The Mediterranean diet pattern is particularly well-suited to this goal, combining high vegetable and legume intake with olive oil and minimal processed food in a way that structurally supports oestrogen excretion alongside broader cardiometabolic benefit.

Alcohol Reduction

Alcohol deserves specific mention as a dietary intervention because of its multiple adverse effects on oestrogen metabolism. It upregulates aromatase activity (increasing oestrogen production from androgens), inhibits hepatic oestrogen clearance, depletes B vitamins required for methylation and Phase 2 conjugation, and promotes gut dysbiosis. Even moderate alcohol consumption (1–2 standard drinks daily) has been associated with measurable elevations in circulating oestrogen levels in multiple prospective studies. For women with clinically significant estrogen dominance, alcohol reduction or elimination is the single highest-impact dietary modification available.

Herbal Support: Mechanisms and Evidence

Chasteberry (Vitex agnus-castus) for Luteal Phase Progesterone Support

Chasteberry (Vitex) is the most extensively studied herbal medicine for luteal phase insufficiency and PMS. Its primary mechanism appears to be dopaminergic activity in the anterior pituitary, which suppresses prolactin secretion. Elevated prolactin is a common cause of luteal phase dysfunction — it suppresses LH pulsatility and reduces progesterone production by the corpus luteum.

Multiple randomised controlled trials support Vitex for PMS and cyclic mastalgia. A 2001 BMJ trial (Schellenberg) demonstrated significant superiority over placebo across five PMS symptom categories. Vitex is most usefully prescribed for women with documented luteal phase insufficiency, elevated prolactin, or cycle-related symptoms consistent with progesterone deficiency. Standard dosing is 160–240 mg of standardised extract daily, taken in the morning, with effects typically evident after 2–3 menstrual cycles.

Milk Thistle (Silybum marianum) for Hepatic Phase 2 Support

Silymarin, the active flavonolignan complex from milk thistle, supports Phase 2 liver conjugation through multiple mechanisms: upregulation of glucuronyl transferase and glutathione S-transferase enzyme activity, reduction of hepatic oxidative stress, and hepatocyte membrane protection. In the context of estrogen dominance, milk thistle supports the liver's capacity to conjugate and clear oestrogen metabolites efficiently. It is a foundational herbal choice when the clinical picture includes signs of hepatic congestion or when the DUTCH panel shows elevated Phase 1 metabolites with evidence of sluggish Phase 2 clearance.

Rosemary (Rosmarinus officinalis) and CYP1A1 Induction

Rosemary extracts — particularly the diterpene carnosol — have demonstrated CYP1A1-inducing activity in in vitro research, suggesting a potential role in promoting the 2-OH oestrogen pathway at the expense of the 4-OH (CYP1B1) pathway. Human clinical data are limited, but rosemary extract is a low-risk adjunct within a broader protocol targeting oestrogen metabolite ratios. Its anti-inflammatory and antioxidant properties provide additional rationale in the context of catechol oestrogen-associated oxidative burden.

The Gut-Oestrogen Axis: Treating Dysbiosis as Primary

The connection between small intestinal bacterial overgrowth and estrogen dominance is underappreciated but mechanistically direct. SIBO creates a dysbiotic environment that drives beta-glucuronidase-producing bacterial overgrowth, impairs Phase 2 oestrogen conjugation by depleting B vitamins (particularly B6 and B12 required for methylation), and generates systemic inflammation that upregulates aromatase activity.

In clinical practice, women with estrogen dominance symptoms who also report IBS-like symptoms, bloating, alternating bowel habits, or a history of repeated antibiotic courses should be prioritised for SIBO breath testing (lactulose or glucose substrate) and comprehensive stool microbiome assessment (GI-MAP or equivalent). Where dysbiosis is confirmed, treating the gut-oestrogen axis as primary — rather than addressing hormones directly — often produces more sustained results and avoids the common pattern of temporary symptom improvement that returns when the gut environment is not corrected.

Probiotic support, particularly Lactobacillus-dominant formulations, has been shown to reduce faecal beta-glucuronidase activity and improve oestrogen excretion in early human trials. Lactulose fermentation by Lactobacillus acidophilus and L. rhamnosus produces lactic acid that acidifies the colonic environment and inhibits beta-glucuronidase-producing Gram-negative species.

Methylation Support: Active B Vitamins for COMT and MTHFR

Given that COMT-mediated methylation of catechol oestrogens is a critical Phase 2 clearance step, ensuring adequate methylation capacity is non-negotiable in estrogen dominance management.

Clinically, this means:

Methylfolate (5-MTHF): Bypasses MTHFR enzyme impairment; 400–800 mcg daily is an appropriate starting dose for patients with confirmed or suspected MTHFR variants. Avoid folic acid (synthetic, non-methylated form) in this population.
Methylcobalamin (active B12): Works synergistically with methylfolate to support the methylation cycle and SAMe regeneration; 1000 mcg daily sublingually is a practical clinical dose.
Magnesium: A cofactor for COMT enzyme function. Magnesium glycinate or malate at 300–400 mg daily is well-tolerated and addresses the widespread deficiency common in this population.
Riboflavin (B2): An MTHFR enzyme cofactor; deficiency compounds MTHFR variant impairment. 100 mg daily is sufficient.

Ordering DUTCH testing with the oestrogen methylation ratio (2-MeO-E1 / 2-OH-E1) provides an objective marker for tracking improvement in COMT-mediated oestrogen clearance in response to methylation support.

Lifestyle Interventions: Stress, Body Composition, and Plastics Avoidance

Cortisol and the Progesterone Axis

Progesterone and cortisol share a common biosynthetic precursor: pregnenolone. Under conditions of chronic psychological stress, adrenal demand for cortisol production diverts pregnenolone toward the glucocorticoid pathway at the expense of progesterone synthesis — a phenomenon sometimes described as pregnenolone steal. While the metabolic pathway is well-established, the clinical significance of steal under real-world stress conditions is debated. What is more robustly supported is that chronic HPA axis activation is associated with anovulatory cycles and luteal phase insufficiency in multiple human studies — independent of the direct pregnenolone mechanism.

Practical stress reduction modalities with documented HPA axis effects include mindfulness-based stress reduction (MBSR, supported by multiple RCTs for cortisol normalisation), diaphragmatic breathing protocols (parasympathetic activation), and structured sleep hygiene. These are not optional lifestyle recommendations — in the naturopathic framework, chronic stress management is a mechanistically necessary component of estrogen dominance treatment.

Body Composition and Aromatase

Given the aromatase-adiposity relationship detailed above, body composition optimisation is a therapeutic target in overweight or obese patients with estrogen dominance. A 2012 study in the Journal of Clinical Oncology demonstrated that intentional weight loss in post-menopausal women produced significant reductions in circulating oestrogens proportional to the degree of fat loss. For perimenopausal and post-menopausal women navigating weight loss after 40, the hormonal dimension of adipose aromatase activity makes body composition a clinical target, not merely an aesthetic one. The clinical implication is that body composition interventions — through appropriately designed dietary and exercise programmes — are as mechanistically relevant as any supplement protocol in this population.

Resistance training merits specific mention: skeletal muscle tissue has lower aromatase activity than adipose tissue and supports insulin sensitivity, which in turn raises SHBG and reduces free oestrogen bioavailability. A programme incorporating 2–3 sessions of progressive resistance training per week is a mechanistically justified recommendation for most patients with estrogen dominance.

Reducing Xenoestrogen Load

Practical, evidence-informed xenoestrogen reduction strategies:

Replace plastic food storage containers with glass or stainless steel; never heat food in plastic
Avoid drinking from single-use plastic water bottles, particularly in warm conditions
Use fragrance-free personal care products; check the Environmental Working Group (EWG) Skin Deep database for paraben and phthalate status
Prioritise organic produce for the EWG's "Dirty Dozen" list (highest pesticide residue crops)
Avoid handling thermal paper receipts when possible (BPA dermal absorption is documented)
Filter drinking water (reverse osmosis or high-quality activated carbon block filters remove many endocrine-disrupting compounds)

A Note on Research-Grade Wellness Compounds

Broader hormonal regulation research increasingly explores signalling pathways that intersect with sex hormone balance, inflammation, and tissue remodelling. Practitioners and patients interested in research-grade wellness compounds relevant to hormonal health will find a growing body of mechanistic work examining how endogenous regulatory peptides interact with steroidogenic and metabolic pathways. This remains an area of active investigation rather than established clinical protocol, but the systems-biology framing aligns with naturopathic principles of addressing root regulatory mechanisms rather than isolated endpoints.

Putting It Together: A Naturopathic Assessment Framework

A comprehensive naturopathic assessment for suspected estrogen dominance should address all six root cause domains rather than defaulting to a single intervention. The clinical sequence:

History and symptom review: Menstrual pattern, PMS severity, breast symptoms, digestive function (dysbiosis flags), stress history, plastics and chemical exposure, alcohol intake, body composition trajectory
Testing: DUTCH test (mid-luteal phase), serum oestradiol and progesterone (timed), SHBG, FSH, fasting insulin, thyroid panel; consider SIBO breath test and GI-MAP if digestive symptoms are present
Interpret the metabolite map: Identify the dominant pathophysiological driver — is this primarily a methylation problem (low 2-MeO / 2-OH ratio), a dysbiosis problem (clinical picture plus history), an aromatase problem (elevated BMI, high alcohol), or a progesterone deficiency (low pregnanediol, anovulatory pattern)?
Tier interventions by root cause: Lead with the highest-impact intervention for the dominant driver. Alcohol elimination, body composition work, and dysbiosis treatment typically produce the most substantial and durable shifts. Layer in dietary (DIM, flaxseed, calcium-D-glucarate, fibre), herbal (Vitex, milk thistle, rosemary), and methylation support as secondary and tertiary interventions.
Monitor and reassess: Repeat DUTCH testing at 3–6 months to objectively track oestrogen metabolite ratios and methylation markers. Symptom improvement without biochemical normalisation suggests incomplete root cause treatment.

Clinical Summary

Estrogen dominance is a multisystem hormonal imbalance defined by the oestrogen:progesterone ratio rather than absolute oestrogen levels. Its root causes span hepatic detoxification pathways, methylation enzyme function, gut microbiome ecology, xenoestrogen exposure, adipose aromatase activity, and luteal phase progesterone production. The DUTCH test provides the most clinically comprehensive biochemical map for identifying the dominant pathophysiological driver in individual patients.

Evidence-ranked dietary interventions include DIM from cruciferous vegetables, flaxseed lignans, calcium-D-glucarate, dietary fibre, and alcohol reduction — with alcohol reduction representing the highest single-intervention impact for most clinical presentations. Herbal support with Vitex (progesterone axis), milk thistle (Phase 2 hepatic conjugation), and rosemary (2-OH pathway induction) provides targeted mechanistic support. Active B vitamins (methylfolate, methylcobalamin) address COMT and MTHFR-driven methylation deficits. Gut dysbiosis treatment is a primary rather than secondary intervention when the oestrobolome is implicated. Stress reduction and body composition optimisation address the adrenal-progesterone relationship and aromatase activity respectively.

This is an area of naturopathic medicine where mechanistic science and clinical practice are closely aligned — and where a thorough, root-cause assessment consistently outperforms single-target hormone interventions.

Key References

Bradlow HL, et al. "2-hydroxyestrone: the 'good' estrogen." Journal of Endocrinology 1996; 150:S259–S265.
Plottel CS, Blaser MJ. "Microbiome and malignancy." Cell Host & Microbe 2011; 10(4):324–335.
Kwa M, et al. "The intestinal microbiome and estrogen receptor-positive female breast cancer." Journal of the National Cancer Institute 2016; 108(8).
Schellenberg R. "Treatment for the premenstrual syndrome with agnus castus fruit extract." BMJ 2001; 322:134.
Walaszek Z, et al. "Dietary glucarate as anti-promoter of 7,12-dimethylbenz[a]anthracene-induced mammary tumorigenesis." Carcinogenesis 1986; 7(9):1463–1466.
Fowke JH, et al. "Urinary oestrogen metabolites and breast cancer: a case-control study." British Journal of Cancer 2003; 88(9):1634–1641.
Sturgeon SR, et al. "Effect of flaxseed consumption on urinary levels of estrogen metabolites in postmenopausal women." Nutrition and Cancer 2010; 62(2):175–180.
Friedenreich CM, et al. "Effect of intentional weight loss on circulating oestrogens in postmenopausal women." Journal of Clinical Oncology 2012.